Zydus launches Topiramate Extended-Release Capsules
Zydus is the first company to receive final approval and launch Topiramate Extended-Release Capsules, USP 25 mg, 50 mg, and 100 mg in the United States.
Zydus is the first company to receive final approval and launch Topiramate Extended-Release Capsules, USP 25 mg, 50 mg, and 100 mg in the United States.
The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”
The PharmaEssentia Innovation Research Center (PIRC) will advance the company’s diverse pipeline and research footprint in the U.S., driving job creation
Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations
The collaboration with IIT Kanpur will build on this foundation and expand the domain of research and development in healthcare technology
It ensures sufficient serum estradiol levels to alleviate menopausal symptoms
BDRs journey for the treatment of Prostate Cancer started with Abiratarone Acetate, then Leuprolide Acetate followed by Enzalutamide and, then Degarelix and Triptorelin.
The proposed initiative is conceptualised with an objective to identify, support, and promote innovative research ideas in healthcare research
The company is one of the most profitable companies manufacturing speciality chemicals in India
Triazolam tablets are used on a short-term basis to treat insomnia (difficulty falling asleep or staying asleep)
Subscribe To Our Newsletter & Stay Updated